{"id":"lorviqua","rwe":[],"tags":[],"phase":"preclinical","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT04800822","NCT05948462","NCT05599412","NCT02925234"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2024","type":"negative","milestone":"Phase 1 Initiated","description":"Phase 1 trial (PF-07284892 in Participants With Advanced Solid Tumors) — Solid Tumor. Trial terminated early."},{"date":"2025","type":"neutral","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kina) — Lung Cancer"}],"aiSummary":"Lorviqua is an orally administered small molecule inhibitor of the ALK tyrosine kinase receptor. It is used to treat non-small cell lung cancer (NSCLC) and is administered in a 100 mg dose.","brandName":"Lorviqua","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1","novelty":"","modality":"","drugClass":"As provided in real world practice","explanation":"Some lung cancers have a genetic abnormality where two genes fuse together to create an overactive ALK protein. This abnormal protein sends constant growth signals that cause cancer cells to multiply uncontrollably. Lorviqua is a targeted drug that blocks this faulty ALK protein, essentially turning off the cancer's growth engine.\n\nWhat makes Lorviqua special is its ability to reach cancer cells in the brain. Many cancer drugs are too large or the wrong chemical shape to cross from the bloodstream into brain tissue, so brain tumors continue growing even when the drug controls cancer elsewhere in the body. Lorviqua's unique design allows it to penetrate this protective barrier and kill cancer cells hiding in the brain.\n\nAdditionally, some patients initially respond well to earlier ALK-blocking drugs but eventually develop resistance when the cancer mutates to avoid the drug's effects. Lorviqua is designed to overcome many of these resistance mutations, making it effective even after previous ALK inhibitor treatments have stopped working.","oneSentence":"As provided in real world practice","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"lorviqua","indications":{"approved":[{"name":"ALK fusion gene-positive non-small-cell lung cancer","diseaseId":"alk-fusion-gene-positive-non-small-cell-lung-cancer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Non-small cell lung cancer","diseaseId":"non-small-cell-lung-cancer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[{"name":"Metastatic ALK+ Non Small Cell Lung Cancer","phase":"preclinical","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04800822","phase":"Phase 1","title":"PF-07284892 in Participants With Advanced Solid Tumors","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":53,"indication":"Solid Tumor","completionDate":"2024-06","primaryEndpoint":"The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lor"},{"nctId":"NCT05948462","phase":"Phase 2","title":"Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kina","status":"Withdrawn","sponsor":"SCRI Development Innovations, LLC","isPivotal":false,"enrollment":0,"indication":"Lung Cancer","completionDate":"2025-03","primaryEndpoint":"This clinical trial is an open-label, single arm study evaluating the safest dose of lorlatinib in combination with standard of care chemotherapy in participants with metastatic anaplastic lymphoma ki"},{"nctId":"NCT05599412","phase":"N/A","title":"Post Marketing Surveillance(PMS) Study of Lorviqua in Korea","status":"Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":600,"indication":"Metastatic ALK+ Non Small Cell Lung Cancer","completionDate":"2028-03","primaryEndpoint":"The objective of this study is to monitor the usage of Lorviqua in real practice within label, including the adverse events associated with Lorviqua"},{"nctId":"NCT02925234","phase":"Phase 2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"Recruiting","sponsor":"The Netherlands Cancer Institute","isPivotal":false,"enrollment":1550,"indication":"Cancer","completionDate":"2027-09","primaryEndpoint":"This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs\\* prescribed for treatment of patients with ad"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL3286830","pubchemSID":"187051779"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}